Development and predictive validity of the cirrhosis-associated ascites symptom scale: A cohort study of 103 patients
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Development and predictive validity of the cirrhosis-associated ascites symptom scale : A cohort study of 103 patients. / Riedel, Agnete Nordheim; Kimer, Nina; Jensen, Anne-Sofie Houlberg; Dahl, Emilie Kristine; Israelsen, Mads; Aamann, Luise; Gluud, Lise Lotte.
In: World Journal of Gastroenterology, Vol. 24, No. 15, 2018, p. 1650-1657.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Development and predictive validity of the cirrhosis-associated ascites symptom scale
T2 - A cohort study of 103 patients
AU - Riedel, Agnete Nordheim
AU - Kimer, Nina
AU - Jensen, Anne-Sofie Houlberg
AU - Dahl, Emilie Kristine
AU - Israelsen, Mads
AU - Aamann, Luise
AU - Gluud, Lise Lotte
PY - 2018
Y1 - 2018
N2 - AIM: To develop a scale of domains associated with the health-related quality-of-life (HRQOL) in patients with cirrhosis-related ascites.METHODS: We initially undertook literature searches and a qualitative study in order to design a cirrhosis-associated ascites symptom (CAS) scale describing symptoms with a potential detrimental impact on health related quality of life (HRQL) (the higher the score, the worse the symptoms). Discriminatory validity was assessed in a validation cohort including cirrhotic patients with (1) tense/severe; (2) moderate/mild; or (3) no ascites (controls). Patients also completed chronic liver disease questionnaire (CLDQ) and the EuroQoL 5-Dimensions 5-Level (EQ-5D-5L) questionnaire evaluating HRQL. The relation between scale scores was analysed using Spearman correlations.RESULTS: The final CAS scale included 14 items. The equivalent reliability was high (Chronbach's alpha 0.88). The validation cohort included 103 patients (72% men, mean age 62.4 years). The mean scores for each question in the CAS scale were higher for patients with severe/tense ascites than for mild/moderate ascites and controls. Compared with controls (mean = 9.9 points), the total CAS scale score was higher for severe/tense ascites (mean = 23.8 points) as well as moderate/mild ascites (mean = 18.6 points) (P < 0.001 both groups). We found a strong correlation between the total CAS and CLDQ score (rho = 0.82, P < 0.001) and a moderate correlation between the CAS and the EQ-5D-5L score (0.67, P < 0.001).CONCLUSION: The CAS is a valid tool, which reflects HRQOL in patients with ascites.
AB - AIM: To develop a scale of domains associated with the health-related quality-of-life (HRQOL) in patients with cirrhosis-related ascites.METHODS: We initially undertook literature searches and a qualitative study in order to design a cirrhosis-associated ascites symptom (CAS) scale describing symptoms with a potential detrimental impact on health related quality of life (HRQL) (the higher the score, the worse the symptoms). Discriminatory validity was assessed in a validation cohort including cirrhotic patients with (1) tense/severe; (2) moderate/mild; or (3) no ascites (controls). Patients also completed chronic liver disease questionnaire (CLDQ) and the EuroQoL 5-Dimensions 5-Level (EQ-5D-5L) questionnaire evaluating HRQL. The relation between scale scores was analysed using Spearman correlations.RESULTS: The final CAS scale included 14 items. The equivalent reliability was high (Chronbach's alpha 0.88). The validation cohort included 103 patients (72% men, mean age 62.4 years). The mean scores for each question in the CAS scale were higher for patients with severe/tense ascites than for mild/moderate ascites and controls. Compared with controls (mean = 9.9 points), the total CAS scale score was higher for severe/tense ascites (mean = 23.8 points) as well as moderate/mild ascites (mean = 18.6 points) (P < 0.001 both groups). We found a strong correlation between the total CAS and CLDQ score (rho = 0.82, P < 0.001) and a moderate correlation between the CAS and the EQ-5D-5L score (0.67, P < 0.001).CONCLUSION: The CAS is a valid tool, which reflects HRQOL in patients with ascites.
KW - Aged
KW - Ascites/diagnosis
KW - Cohort Studies
KW - Cross-Sectional Studies
KW - Denmark
KW - Female
KW - Humans
KW - Liver Cirrhosis/complications
KW - Male
KW - Middle Aged
KW - Quality of Life
KW - Reproducibility of Results
KW - Surveys and Questionnaires
U2 - 10.3748/wjg.v24.i15.1650
DO - 10.3748/wjg.v24.i15.1650
M3 - Journal article
C2 - 29686472
VL - 24
SP - 1650
EP - 1657
JO - World Chinese Journal of Digestology
JF - World Chinese Journal of Digestology
SN - 1009-3079
IS - 15
ER -
ID: 215866880